تحلیل اختیاری محصول
با اجازه شما، از تحلیلهای محدود و حریمخصوصیمحور استفاده میکنیم تا مسیرهای پژوهشی مؤثر را بشناسیم. از ردیاب تبلیغاتی یا بازپخش نشست استفاده نمیکنیم. این انتخاب را میتوانید در تنظیمات تغییر دهید. بخوانید سیاست حفظ حریم خصوصی.
Stryker Corporation's published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $114.2B | |
|---|---|---|
| Revenue (ttm) | 25.8B | |
| Net income (ttm) | 3.7B | |
| EPS (ttm) | $9.65 | |
| Shares out | 383.6M | |
| P/E (trailing) | 31.5x | |
| P/E (forward) | 16.5x | |
| Dividend | $3.52 (1.16%) | |
| Volume | 1,512,185 | |
| Beta | 0.78 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $17.11B | $18.45B | $20.50B | $22.60B | $25.12B | +10.1% |
| Gross profit | $10.97B | $11.58B | $13.06B | $14.44B | $16.07B | +10.0% |
| Operating income | $2.58B | $2.84B | $3.89B | $3.69B | $4.89B | +17.3% |
| Net income | $1.99B | $2.36B | $3.17B | $2.99B | $3.25B | +13.0% |
| EPS (diluted) | $5.21 | $6.17 | $8.25 | $7.76 | $8.40 | +12.7% |
| EBITDA | $3.61B | $4.02B | $5.06B | $6.01B | $6.31B | +15.0% |
| R&D | $1.24B | $1.45B | $1.39B | $1.47B | $1.62B | +7.1% |
| SG&A | $6.43B | $6.39B | $7.11B | $7.69B | $8.65B | +7.7% |
Recent company headlines from major financial publishers.
Accelerated hospital capital equipment spending, record Mako robotic placements in hospital and ASC settings, and rapid clearance of Peripheral Vascular backorders drive double-digit earnings compounding and accelerated operating margin expansion ahead of house expectations.
Stryker executes within its guided organic sales growth corridors, transitioning to steady high-single-digit revenue expansion through FY2030 supported by resilient reconstructive procedure volumes and steady operating margin progression.
| Ke ↓ / g → | 2.5% | 2.8% | 3.0% | 3.3% | 3.5% |
|---|---|---|---|---|---|
| 7.6% | $346 | $357 | $368 | $381 | $395 |
| 8.1% | $321 | $329 | $338 | $348 | $359 |
| 8.6% | $299 | $306 | $313 | $321 | $330 |
| 9.1% | $280 | $286 | $292 | $299 | $306 |
| 9.6% | $264 | $269 | $274 | $279 | $285 |
Upcoming earnings date and setup when available.
رتبهای که نسخهٔ پژوهشی منتشرشدهٔ هر ماه داشت. رتبه قیمت در تاریخ تحلیل را با ارزش منصفانه مقایسه میکند و سابقهای از درستی یا نادرستی ارزیابی نیست.
| سال | دی | بهمن | اسفند | فروردین | اردیبهشت | خرداد | تیر | مرداد | شهریور | مهر | آبان | آذر |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
